NSE filing, NSE: COHANCE. Summary written from the filing by ALFA Finder's alert engine.
Cohance Lifesciences Ltd: key numbers
- Share price
- ₹476.05
- Market cap
- ₹18,214 Cr
- Revenue (annual)
- ₹2,269 Cr
- Net profit (annual)
- ₹179.2 Cr
- P/E (TTM)
- 171.4×Sector 46.1×
- Promoter holding
- 57.48%-0.01% QoQ
- FII holding
- 7.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cohance Lifesciences Ltd
All →Cohance Lifesciences Board Meeting Date
Cohance Lifesciences will hold a board meeting on 6 November 2026 to approve Q2 and half-year results. The trading window stays closed until 9 November 2026.
Cohance Lifesciences Other Announcement
Cohance Lifesciences Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b), disclosing promoter and public shareholding data as of September 30, 2026.
Cohance Lifesciences Regulatory Approval
Cohance Lifesciences received Central Government approval for the appointment of Mr. Umang Vohra as Chairman and Group CEO.
Cohance Lifesciences Management Change
Cohance Lifesciences appointed Mr. Abhimanyu Ojha as the new Chief Financial Officer and Key Managerial Personnel, effective October 12, 2026.
Cohance Lifesciences Other Announcement
Cohance Lifesciences received a voluntary ESG Rating of Crisil ESG 61 (Strong) from Crisil ESG Ratings. No capital or business event is involved.
Cohance Lifesciences Business Update
Cohance Lifesciences completed a USFDA inspection at its Jaggaiahpet API facility, receiving a Form 483 with five observations. The company has initiated corrective and preventive actions.
Other employee stock options announcements
All →RateGain Travel Technologies Employee Stock Options
RateGain granted 53,021 Stock Appreciation Rights under its SAR Scheme 2022 at ₹800 and ₹862.25 per unit. The grants vest over four years and are exercisable within three years of vesting.
- Execution
- Vesting over 4 years (10% Y1, 20% Y2, 30% Y3, 40% Y4); exercisable within 3 years of vesting
Aye Finance Employee Stock Options
Aye Finance's employee welfare trust transferred 89,501 equity shares to grantees on exercising ESOP options. The share capital remains unchanged, so no new issuance occurs.
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.
OnEMI Technology Solutions Employee Stock Options
OnEMI Technology allotted 69,000 equity shares on exercise of employee stock options under the Kissht ESOP 2022 plan. The shares rank pari passu with existing equity.
Bliss GVS Pharma Employee Stock Options
Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.
Bandhan Bank Employee Stock Options
Bandhan Bank's board granted 32,98,871 stock options under ESOP Series 1 (Tranche 9) at Rs 151.91 per option. The options vest over four years, with each option convertible into one equity share.